Exercise and Beetroot Juice for Peripheral Arterial Disease
(IMPACT PAD Trial)
Trial Summary
What is the purpose of this trial?
Lower extremity revascularization combined with supervised exercise significantly improves walking performance compared to revascularization alone in people who have PAD without limb threatening ischemia. However, supervised exercise is inaccessible or burdensome for most PAD patients. We hypothesize that home-based exercise combined with lower extremity revascularization will significantly improve walking performance compared to revascularization alone in patients with PAD undergoing revascularization for disabling PAD. We further hypothesize that inorganic nitrate, a major source of nitric oxide (NO) abundant in beetroot juice, will improve walking performance after lower extremity revascularization, compared to placebo. In preclinical models, NO inhibits inflammation, neointimal hyperplasia, thrombosis, and vascular smooth muscle cell migration at sites of revascularization. NO increases angiogenesis and perfusion, repairs skeletal muscle damaged by ischemia, and stimulates mitochondrial activity. In a randomized clinical trial with a 2 x 2 factorial design, we will test the following two primary hypotheses in 386 patients randomized within three months of a successful lower extremity revascularization for disabling PAD: First, that home-based exercise combined with lower extremity revascularization will improve six-minute walk distance more than revascularization alone at 6-month follow-up (Primary Aim #1). Second, that nitrate-rich beetroot juice combined with lower extremity revascularization will improve six-minute walk, compared to placebo combined with revascularization at 6-month follow-up (Primary Aim #2).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you are currently taking sildenafil, tadalafil, or related drugs. Additionally, you must stop consuming beetroot juice, oral nitrate or nitrite, or beetroot supplements for 30 days before the trial and throughout the study.
What data supports the effectiveness of this treatment for peripheral arterial disease?
Is it safe to use beetroot juice and exercise for peripheral arterial disease?
Research shows that beetroot juice, which is high in dietary nitrate, is generally safe for humans and can help lower blood pressure and improve exercise performance in conditions like peripheral arterial disease and COPD (a lung condition). No significant safety concerns were reported in the studies reviewed.12467
How does the treatment of exercise and beetroot juice differ from other treatments for peripheral arterial disease?
This treatment is unique because it combines exercise with beetroot juice, which is rich in dietary nitrate. The nitrate in beetroot juice can improve blood flow and oxygen delivery to muscles, enhancing exercise performance and walking ability in patients with peripheral arterial disease, unlike traditional treatments that may not focus on dietary components.13467
Eligibility Criteria
This trial is for patients with Peripheral Artery Disease (PAD) who have undergone revascularization but still experience walking difficulties. Participants should be within three months post-successful revascularization and willing to follow a home-based exercise program or consume beetroot juice.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in home-based exercise and consume nitrate-rich beetroot juice or placebo for six months
Follow-up
Participants are monitored for changes in six-minute walk distance and other mobility measures
Extended Follow-up
Participants are monitored for long-term outcomes such as prevention of hemodynamic failure and mobility improvements
Treatment Details
Interventions
- Home Based Exercise
- Nitrate Rich Beetroot Juice
- Placebo Beetroot Juice Without Nitrate
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor